Gilead and Genesis Therapeutics Partner on AI-Driven Small Molecule Therapies

Partnership Overview:
Gilead Sciences and Genesis Therapeutics have entered a strategic collaboration to discover and develop novel small molecule therapies using artificial intelligence (AI).

AI Platform:
The collaboration will utilize Genesis's AI platform, Genesis Exploration of Molecular Space (GEMS), to generate and optimize molecules for targets selected by Gilead.

Financial Terms:
Genesis will receive an upfront payment of $35 million for three specified targets, with options for Gilead to propose additional targets for an additional fee. Genesis is also eligible for preclinical, developmental, regulatory, and commercial milestone payments, as well as tiered royalties on net product sales.

Focus:
The partnership will focus on preclinical studies, with Gilead retaining exclusive rights for clinical development and potential commercialization of the developed compounds.

Goals:
The collaboration aims to leverage AI to expedite the discovery of molecules for challenging targets and address significant unmet patient needs.

Genesis Background:
Genesis Therapeutics has raised over $300 million in funding to establish a pipeline focused on addressing significant medical conditions using its AI platform.

Gilead Background:
Gilead Sciences is a biopharmaceutical company committed to advancing innovative medicines to prevent and treat life-threatening diseases.